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Abstract. Several childhood multisystem disorders with prominent ophthalmological manifesta- 
tions have been ascribed to the malfunction of the peroxisome, a subcellular organelle. The 
peroxisomal disorders have been divided into three groups: 1) those that result from defective 
biogenesis of the peroxisome (Zellweger syndrome, neonatal adrenoleukodystrophy, and infan- 
tile Refsum’s disease); 2) those that result from multiple enzyme deficiencies (rhizomelic chon- 
drodysplasia punctata); and 3) those that result from a single enzyme deficiency (X-linked 
adrenoleukodystrophy, primary hyperoxaluria type 1). Zellweger syndrome, the most lethal of 
the three peroxisomal biogenesis disorders, causes infantile hypotonia, seizures, and death 
within the first year. Ophthalmic manifestations include cornea1 opacification, cataract, glauco- 
ma, pigmentary retinopathy and optic atrophy. Neonatal adrenoleukodystrophy and infantile 
Refsum’s disease appear to be genetically distinct, but clinically, biochemically, and pathological- 
ly similar to Zellweger syndrome, although milder. Rhizomelic chondrodysplasia punctata, a 
peroxisomal disorder which results from at least two peroxisomal enzyme deficiencies, presents 
at birth with skeletal abnormalities and patients rarely survive past one year of age. The most 
prominent ocular manifestation consists of bilateral cataracts. X-linked (childhood) adrenoleu- 
kodystrophy, results from a deficiency of a single peroxisomal enzyme, presents in the latter part 
ofthe first decade with behavioral, cognitive and visual deterioration. The vision loss results from 
demyelination of the entire visual pathway, but the outer retina is spared. Primary hyperoxaluria 
type I manifests parafoveal subretinal pigment proliferation. Classical Refsum’s disease may also 
be a peroxisomal disorder, but definitive evidence is lacking. Early identification of these disor- 
ders, which may depend on recognizing the ophthalmological findings, is critical for prenatal 
diagnosis, treatment, and genetic counselling. Sure Ophthalmol 35:353-368, 1991) 
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As the result of recent developments in cellular 
biochemistry, a group of childhood diseases with 
prominent ophthalmological manifestations can 
now be attributed to the malfunction of a subcel- 
lular organelle called the “peroxisome.” Discov- 
ered in 1954, the peroxisome is known to harbor a 
large number of important catabolic and anabolic 
reactions, among them the degradation of very- 
long-chain fatty acids. The build-up of these very- 
long-chain fatty acids and characteristic ocular 
abnormalities are principal markers of the peroxi- 
somal disorders. 
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I. The Peroxisome 
A. HISTORICAL PERSPECTIVE 
While observing mouse kidney cells in 1954, 
Rhodin noted a single membrane-bound organelle 
with a granular matrix measuring about one-half 
micrometer which he called simply a “microbody.“1’2 
A few years later, de Duve et a12’ discovered that this 
microbody oxidized certain substrates by utilizing 
molecular oxygen (0,) and producing hydrogen 
peroxide (H202), leading them to designate this or- 
ganelle the “peroxisome.” 
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Peroxisomes are believed to be present in nearly 
all human cells, including those of the eye,g0 but 
their abundance and distribution vary depending 
upon the developmental stage of the tissue. Most 
abundant in liver and kidney cells, they are also 
present during the first two weeks of life in neurons 
of the cerebrum and cerebellum.* They are espe- 
cially numerous in oligodendrocytes, which are re- 
sponsible for myelin formation within the central 
nervous system. 
B. BIOGENESIS 
Peroxisomal enzymes are encoded by nuclear 
genes and are synthesized on cytoplasmic poly- 
somes. 68 The enzymes then enter preformed per- 
oxisomes post-translationally.6a~‘1 With one known 
exception (beta-ketoacyl-CoA thiolase), peroxisom- 
al enzymes have been shown to be synthesized in 
their final form, not requiring proteolytic cleavage 
for activation.80 Once formed, peroxisomes are be- 
lieved to grow to a certain size and then split in two. 
In those childhood disorders ascribed to imperfect 
biogenesis of peroxisomes, many enzymes cannot 
be incorporated into the peroxisomes. Stranded in 
the cytosol, these enzymes and the “ghost” peroxi- 
somes are rapidly degraded.‘24 
C. CATABOLIC REACTIONS 
The best understood catabolic reaction of the 
peroxisome is the oxidative degradation of long- 
chain fatty acids, those with 16 or more carbon 
atoms. Very-long-chain fatty acids, those with 22 or 
more carbon atoms, are oxidized exclusively in the 
peroxisome.‘30 The organelle is also involved in 
pipecolic acid metabolism in primates,70~7g cellular 
oxidation reactions generating H202*‘, and possibly 
phytanic acid metabolism. 
1. Very-long-chain Fatty Acid Degradation 
The shorter-chain fatty acids enter the mitochon- 
drion by a carnitine acyl transferase carrier system 
and are catabolized by a process known as beta- 
oxidation, which consists of the repeated removal of 
two carbon fragments in the form of acetyl-CoA 
from the carboxyl end of the fatty acid molecule. 
The acetyl-CoA then enters the tricarboxylic acid 
(Krebs) cycle and generates energy for the cell. 
Very-long-chain fatty acids, as well as fatty acids 
consisting of 14 or more carbons, are oxidized by a 
similar process, but predominantly in peroxisomes, 
by enzymes which are distinct from their mitochon- 
drial analogs 8*13o (Fig. 1). Another difference is that 
very long-chain fatty acids enter the peroxisome via 
a non-carnitine acyl transferase carrier system.75 
The peroxisomal enzymes involved in very long- 





Fig. 1. Peroxisomal very-long-chain fatty acid degrada- 
tion pathway. Electron micrograph ( x 32,000) of human 
peroxisome of a hepatocyte (Adapted from Sternlieb et 
a1’42 with permission of the authors and the United States 
and Canadian Academy of Pathology, Inc.). 
acyl-CoA ligase, acyl-CoA oxidase, bifunctional pro- 
tein (acyl-CoA hydratase and acyl-CoA dehydro- 
genase), and beta-ketoacyl-CoA thiolase.4g*55,81 Mal- 
function of this pathway leads to a build-up of very 
long-chain fatty acids, the chief biochemical clue to 
the diagnosis of peroxisomal disorders. 
2. Pipecolic Acid 
In primates, the peroxisome is responsible for 
the catabolism of L-pipecolic acid, which is, in turn, 
formed from the catabolism of the amino acid ly- 
sine.43,54,60*61 It has been suggested that the L-pipe- 
colic acid synthetic pathway may be the major 
degradative pathway of lysine in the rain.*‘,” All 
disorders of peroxisomal biogenesis give rise to ab- 
normally high serum levels of pipecolic acid.‘.70~78*‘52 
3. HZOZ-forming Oxidation 
The peroxisome gets its name from its ability to 
oxidize a number of substrates utilizing 0, and 
forming hydrogen peroxide (H202) in the proc- 
ess.*’ The formed H,O, is converted to H,O by the 
peroxisomal enzyme catalase, the main histochemi- 
cal marker of this organelle. When the peroxisomes 
are poorly formed, catalase is found in the cytosol 
rather than in the peroxisomes. 
4. Phytanic Acid Degradation 
Whether the peroxisome is involved in the ca- 
tabolism of phytanic acid remains a debated issue. A 
branched 20-carbon fatty acid of dietary origin, 
phytanic acid undergoes beta-oxidation after an 
initial alpha-oxidation step.‘43,‘53 Evidence for a 
peroxisomal role comes from the work of Van den 
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Branden et al, ‘55 who showed that administration of 
phytol, a precursor of phytanic acid, induces per- 
oxisomal proliferation and leads to a five-fold in- 
crease in peroxisomal acyl-CoA oxidase levels. Fur- 
thermore, an elevated serum phytanic acid level is 
found in the peroxisomal biogenetic disorders. 
D. ANABOLIC REACTIONS 
Anabolic reactions that take place in the peroxi- 
some include ether lipid synthesis (a plasmalogen 
precursor),45 bile acid synthesis,g5 and possibly cho- 
lesterol synthesis. 66 Peroxisomal biogenetic disor- 
ders leave these substances in deficit or pile up ex- 
cessive intermediates. 
1. Ether Lipids 
Peroxisomes prepare ether lipids, the major pre- 
cursors for plasmalogen synthesis, from dihydroxy- 
acetone phosphate. Plasmalogens comprise up to 
20% of mammalian cell membranes135 and 15% of 
myelin lipids. ” Whereas conventional phospholip- 
ids contain an ester-linked fatty acid at the first posi- 
tion of the glycerol backbone, plasmalogens contain 
a 1,2 unsaturated long-chain vinyl ether linkage at 
the first position. The predominant plasmalogen in 
most tissues is phosphatidylethanolamine, although 
heart and liver cell membranes contain predomi- 
nantly phosphatidylcholine.53 The final synthetic 
reactions of plasmalogen synthesis occur in the 
endoplasmic reticulum.47 Defective plasmalogen syn- 
thesis may be partially responsible for some of the 
neurologic manifestations of peroxisomal disorders. 
2. Bile Acids 
Certain steps of bile acid synthesis occur in the 
peroxisome which accounts for the proportionally 
higher levels of bile acid intermediates observed in 
patients with peroxisome biogenesis disorders.g5 
Two bile acid precursors, dihydroxycoprostanic 
acid and trihydroxycoprostanic acid, are detectable 
clinically and may aid in the diagnosis. 
3. Cholesterol 
Peroxisomes may possess a pathway for choles- 
terol synthesis’46 that is distinct from the better 
known microsomal pathway. Disruption of the per- 
oxisomal pathway may lead to the low plasma cho- 
lesterol levels observed in some patients with per- 
oxisomal disorders.” 
II. Peroxisomal Disorders 
The peroxisomal disorders have been divided 
into three groups: those that result from defective 
biogenesis of the organelle, those resulting from 
more than one enzymatic abnormality but with in- 
TABLE 1 
Peroxisomul Disorders as Recorded at the Kenned Institute 
from 1981-l 988 (Adapted from J Moser’ ) 







Rhizomelic chondrodysplasia punctata 
Infantile Refsum’s disease 
Classical Refsum’s disease 
Primary hyperoxaluria type 1 
Insufficient information for 
classification 
Others (including hyperpipecolic 
acidemia and isolated defects of very 













tact peroxisome structure, and those that appear to 
result from one faulty enzyme.*’ The relative fre- 
quency of the various peroxisomal disorders has 
been reported for 1981-1988 from the Kennedy 
Institute8’ (Table 1). 
A. PEROXISOME BIOGENESIS DISORDERS 
(TABLE 2) 
The peroxisomal disorders that result from ab- 
normal biogenesis of the organelle include Zell- 
weger (Cerebro-hepato-renal) syndrome, neonatal 
adrenoleukodystrophy, and infantile Refsum’s dis- 
ease. Disorders of peroxisome biogenesis all share a 
panel of ultrastructural or biochemical abnormali- 
ties,87 which include: 1) absent or reduced numbers 
of peroxisomes; 2) catalase present in the cytosol 
(instead of in the peroxisome); 3) reduced tissue 
levels of plasmalogen; 4) defective oxidation and 
accumulation of very long-chain fatty acids; 5) defi- 
cient oxidation and age-dependent accumulation of 
phytanic acid; 6) defects in certain steps of bile acid 
synthesis and accumulation of bile acid interme- 
diates; 7) defective oxidation and accumulation of 
L-pipecolic acid; and 8) increased urinary excretion 
of dicarboxylic acids due to inadequate H,O,-based 
oxidation. 
Genetic analysis of the peroxisomal biogenesis 
disorders has shown that at least five complementa- 
tion groups (genes) exist.‘5.“* Alteration of any of 
three different genes may result in Zellweger syn- 
drome. Likewise, there are two separate genes 
whose disruption will yield neonatal adrenoleuko- 
dystrophy, and one which can result in infantile 
Refsum’s disease. Because the complementation 
group which encompasses infantile Refsum’s dis- 
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Fig. 2. Z@: Infant with Zellweger 
syndrome, showing severe craniofa- 
cial dysmorphic features: high fore- 
head, hypertelorism, and hypoplas- 
tic supraorbital ridges (Reprinted 
from Smith et al134 with permission 
of the authors and the CV Mosby 
Co.) Right: Infant with Zellweger 
syndrome exhibiting milder dys- 
morphic features: hypertelorism 
and hypoplastic supraorbital ridges 
(courtesy of James McManaway, Ill, 
MD. Hershey, PA). 
ease is also one of the three complementation 
groups for Zellweger syndrome, the disruption of 
one gene may produce either Zellweger syndrome 
or infantile Refsum’s disease. The factors which de- 
termine which of the two diseases will occur are 
currently unknown. 
1. Zellweger Syndrome (Cerebro-hepato-renal 
Syndrome) 
In 1964, Bowen et al” first described a severe 
neonatal disorder with distinctive craniofacial dys- 
morphism marked by a high forehead, epicanthal 
folds, hypoplastic supraorbital ridges and nasal 
TABLE 2 
Peroxisomul Disorders with Ocular Manifestations 
Zellweger Syndrome 
Neonatal 
Adrenoleukodystrophy Infantile Refsum’s Disease 
Inheritance 















Markedly reduced or absent 
Pigmentary retinopathy and 


















Markedly reduced or absent 
Pigmentary retinopathy and 
retinal arteriolar attenuation 
Pigment epithelial clumping 
Optic atrophy 
Extinguished ERG 
Adrenal cortical atrophy 










Markedly reduced or absent 
Pigmentary retinopathy and 










*VLCFA = Very-long-chain fatty acids 
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bridge, micrognathia, high arched palate, and hyper- 
telorism (Fig. 2). The externally apparent ocular ab- 
normalities include corneal clouding,12*44,g3*10, ‘05~‘36*144 
CataraCtS 56,‘X69,~,‘W’~6,‘~ and g~aucoma.‘2,104,105,1~ 
Zellweger syndrome babies also have seizures, 
psychomotor retardation, severe hypotonia, talipes 
equinovarus, limb contractures with limited finger 
extension (camptodactyly), hepatomegaly, severe 
hearing impairment, ventricular septal defects, jaun- 
dice, and hypoprothrombinemia.36,H~‘34*145 Death oc- 
curs within a few months. 
As globes were inspected after death, it became 
evident that the posterior ocular segment is also 
affected, with narrowed retinal arterioles,35~‘3g”57 
retinal pigment clumping,“‘j and optic disc pallor 
and hypoplasia. 22,‘06~13g Most observers have noted 
that the abnormal dispersion of retinal pigment 
lacks the perivascular “bone spicule” pattern associ- 
ated with typical retinitis pigmentosa.22s35 The ex- 
tensive retinal abnormalities were foretold by the 
finding of extinguished electroretinograms in all 
cases.56*‘3g 
The brain pathology of Zellweger syndrome con- 
sists of a failure of neuronal migration and patchy 
demyelination. 28,32*g3~‘56 The areas of demyelination 
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are attended by perivascular macrophages laden 
with inclusions which, on electron microscopy, are 
found to consist of two electron-dense leaflets sepa- 
rated by a lucent space. 94 These inclusions have 
been identified as cholesterol esters of very-long- 
chain fatty acids. 
Several reports have now characterized the oph- 
thalmic pathology. Anteriorly, cornea1 epithelial 
edema,22*44 posterior embryotoxon, cataract,44,56*6g 
and glaucoma have been inconsistently document- 
ed. The cause of the cornea1 clouding is uncertain, 
as no pathologic inclusions have been found in the 
cornea. The cataracts, of variable density, appear to 
be caused by vacuolations of cortical lens fibers. Al- 
though anterior chamber angle anomalies have 
been described, ” the pathogenesis of glaucoma is 
not definite. 
The posterior segment abnormalities are far 
more severe (Fig. 3). Most striking is a loss of pho- 
toreceptors, 35,44,6g.‘56 but all retinal neurons are re- 
duced in number, including retinal pigment epi- 
thelium and ganglion cells.44,156 Scattered through 
the retina and the subretinal space are humerous 
macrophages containing pigment and nonpig- 
mented cytoplasmic bileaflet inclusions identical to 
TABLE 2 
Peroxisomul Disorders with Ocular Manifestations (continued) 
khizomelic X-linked Primary hyperoxaluria 
























Anterior and posterior visu- 
al pathway demyelina- 
tiun 
Normal ERG 
Adrenal cortical atrophy 










First or second decades 
Glyoxalate metabolism 
(deficient alanine : glyox- 
alate aminotransferase) 
Present 
Black parafoveal ringlets 
with or without white fi- 






Urine: Organic acids 
Liver: Alanine : glyoxalate 
aminotransferase in per- 
cutaneous biopsy 
Autosomal recessive 
First to fourth decades 
Phytanic acid oxidation 












Increased CSF protein 
Cardiopathy 
Anosmia 
Plasma: Phytanic acid 
Fibroblasts: Phytanic acid 
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Fig. 3. Midperipheral retina in case of Zellweger syn- 
drome, showing loss of photoreceptors and ganglion 
cells. An aggregate of pigmented macrophages (arrow) is 
present in the subretinal space (hematoxylin and eosin, 
by in situ hybridization in neuronal cells in a latently 
x 290; reprinted from Cohen et al’* with permission of 
the authors and The Ophthalmic Publishing Co., Chica- 
go, IL). 
those seen in the brain. These inclusions are also 
found in the retinal pigment epithelium. The optic 
nerve is profoundly demyelinated, its axons inter- 
leaved with the familiar inclusion-bearing macro- 
phagesuQ The posterior vitreous contains enough 
of these bileaflet-bearing macrophages to appear 
hazy in some cases.” One may speculate that the 
accumulation of very-long-chain fatty acids kills the 
neurons and the myelin-forming oligodendrocytes, 
and that the macrophages scavenge the debris. 
In 1973, Zellweger syndrome became the first 
human disease to be linked to the peroxisome. By 
utilizing histochemical staining procedures, Gold- 
fischer et a13’ were able to show that tissues from 
Zellweger syndrome patients lacked catalase-con- 
taining particles (peroxisomes). Using more sophis- 
ticated techniques, Santos et al”’ have recently 
been able to demonstrate that membrane struc- 
tures similar to peroxisomes are present in Zell- 
weger syndrome patients, but do not contain the 
normal complement of enzymes. Subsequent stud- 
ies confirmed that many peroxisomal enzymes are 
synthesized normally in Zellweger syndrome but 
are not assembled into the organelle and many are 
therefore quickly degraded in the cytoplasm.25~‘5Q 
Zellweger syndrome shares the biochemical pro- 
file common to all peroxisomal biogenetic disor- 
ders, but may be biochemically distinct in having 
the highest very-long-chain fatty acid accumulation 
and lowest level of plasmalogens. 
The diagnosis of Zellweger syndrome should be 
considered in a severely hypotonic infant with sei- 
zures, craniofacial dysmorphism, narrowed retinal 
arterioles, retinal pigment dispersion, and optic 
disc pallor. Cornea1 clouding and cataract are not 
necessary features. With these findings, Zellweger 
syndrome can be distinguished from intrauterine 
infections, Lowe’s syndrome, galactosemia, and ly- 
sozomal storage abnormalities by finding elevated 
plasma very-long-chain fatty acids and reduced 
plasmalogen levels. If these tests are not normal, 
pipecolic acid and bile acids may be measured for 
confirmation. These specialized tests, which are still 
available only in a small number of medical centers, 
have now been extended to prenatal diagnosis.” 
Because Zellweger syndrome is an autosomal reces- 
sive disorder,Q3 genetic counseling of families that 
have had an affected offspring is critical. Unfortu- 
nately, there is yet no treatment available. 
2. Neonatal Adrenoleukodystrophy 
Neonatal adrenoleukodystrophy was first de- 
scribed in 1978 by Ulrich et a1.15* They observed a 
severely hypotonic infant who developed seizures 
at 4 days and died at 20 months. Because their 
patient had adrenal cortical atrophy and patchy 
brain demyelination reminiscent of the already well 
known X-linked adrenoleukodystrophy, they chose 
to label the disease neonatal adrenoleukodystro- 
phy. It subsequently became clear that neonatal 
adrenoleukodystrophy is an autosomal recessive 
disorder which is clinically, pathologically, and bio- 
chemically much closer to Zellweger syndrome 
than to X-linked adrenoleukodystrophy. 
Neonatal adrenoleukodystrophy may look exact- 
ly like Zellweger syndrome and cause death within 
the first year, but more commonly the disease is 
milder than Zellweger syndrome, with patients man- 
ifesting no dysmorphic features and living an aver- 
age of four years - some even into the second dec- 
ade.85,‘“8 patients typically have adrenal cortical 
atrophy, but rarely manifest adrenal insufftciency.67 
Anterior ocular segment abnormalities are uncom- 
mon, but retinal pigmentary degeneration and op- 
tic atrophy are disabling and diagnostically impor- 
tant.63 
We have had the opportunity to perform oph- 
thalmological examinations on two of the longest- 
surviving patients with neonatal adrenoleukodys- 
trophy - brothers aged 12 and 15. In both boys, 
visual acuity was 20/200 OU. The older brother had 
a comitant 30 prism diopter right exotropia, while 
the younger brother’s motility examination was 
normal. Both patients demonstrated smooth ocular 
movements without nystagmus. The pupils of both 
patients reacted moderately, but sluggishly to light, 
Fig. 4. Fundus photographs from right eye (left) and left eye (right) of a 15-year-old boy with Neonatal Adrenoleukodys- 
trophy. Note marked retinal arteriolar attenuation, optic disc pallor, and loss of pigment epithelium especially evident in 
macular area. 
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Fig. 5. Electroretinograms (ERGS) from two boys with neonatal adrenoleukodystrophy, showing extinguished responses. 
Fig. 6. L.@ Retina from patient with neonatal adrenoleu- 
kodystrophy, showing loss of photoreceptor and gangli- 
on cells, similar to that seen in Zellweger Syndrome (he- 
matoxylin and eosin, x 100). Right: Electron micrograph 
x 27,000 of a vitreous macrophage displaying inclusion 
(arrow). Inset ( x 95,000) shows that inclusion consists of 
two electron-dense leaves separated by a central lucent 
zone. (Reprinted from Glasgow et aIs with permission of 
the authors and O#th&zelogy.) 
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Fig. 7. Retina from patient with X- 
linked adrenoleukodystrophy. Note 
loss of ganglion cells but preservation 
of photoreceptors. There is postmor- 
tem artifactual detachment of the 
photoreceptor layer (Hematoxylin 
and eosin, x40; Reprinted from 
Wray et a1’66 with permission of the 
authors and the Ophthalmic Publish- 
ing Co., Chicago, IL). 
and there were no other anterior segment abnor- 
malities. The optic nerves exhibited waxy pallor 
with marked attenuation of the retinal vessels (Fig. 
4). Pigment was clumped and scattered through- 
out the retinal mid-periphery; the perifoveal area 
was markedly depigmented. The electroretinogram 
showed the cone and rod responses to be decreased 
95 to 98% (Fig. 5). 
The pathologic findings of neonatal adrenoleu- 
kodystrophy in the central nervous system are simi- 
lar to those of Zellweger syndrome.’ Ocular patho- 
logic findings are confined to the posterior segment 
but otherwise are identical to those described in 
Zellweger syndrome22~38 (Fig. 6A). Characteristic bi- 
leaflet inclusions are present in the adrenal cortex, 
pigment epithelial cells, photoreceptor cells, and 
retinal and vitreous macrophage? (Fig. 6B). 
The link to the peroxisome came first in 1982, 
when Brown et alI4 demonstrated deficient peroxi- 
somal very-long-chain fatty acid oxidation in tissues 
from neonatal adrenoleukodystrophy patients. 
Then in 1985, Goldfischer et a14’ discovered that 
peroxisomes are significantly reduced in number 
and size in neonatal adrenoleukodystrophy pa- 
tients. It has since been learned that neonatal 
adrenoleukodystrophy patients share the bio- 
chemical aberrations found in Zellweger syndrome 
patients, except that neonatal adrenoleukodys- 
trophy shows increased serum levels of saturated 
very-long-chain fatty acids,63 but normal or re- 
duced levels of mono-unsaturated very-long-chain 
fatty acids.67 
Neonatal adrenoleukodystrophy should be re- 
garded clinically as a mild form of Zellweger syn- 
drome. Patients frequently survive the years of in- 
fancy, show no dysmorphic features, and have 
markedly diminished vision. Because of the retinal 
findings, they may initially be diagnosed as having 
“Leber’s congenital amaurosis”” or suspected of 
having the infantile form of neuronal ceroid lipo- 
fuscinosis.g6~‘50 When hearing loss is present, they 
may be labelled “Usher’s syndrome.” The correct 
diagnosis can now be made, as with Zellweger syn- 
drome, by demonstrating the plasma abnormalities 
shared by the peroxisomal biogenetic disorders. 
3. Infantile Refsum’s Disease 
Infantile Refsum’s disease is the least severe of 
the peroxisome biogenesis disorders, and was first 
described in 1982 by Scotto et a11z6 and Boltshauser 
et al.” They observed patients presenting in the 
first year of life with pigmentary retinopathy, neu- 
rosensory deafness, growth and mental retarda- 
tion, hepatomegaly, and mild facial dysmorphism 
consisting of epicanthal folds, flat nasal bridge, and 
Fig. 8. Fundus photograph from a 2% year old girl with 
Primary hyperoxaluria Type 1 demonstrating confluent, 
black, subretinal parafoveal ringlets and white fibrosis 
(Reprinted from Small et a1’33 with permission of the 
authors and the American Medical Association). 
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low set ears. Increased serum levels of phytanic acid 
led them to surmise that these patients suffered 
from an infantile form of Refsum’s disease, despite 
the fact that adult patients with Refsum’s disease do 
not have facial dysmorphism or cognitive impair- 
ment. 
Although microphthalmia, strabismus, and nys- 
tagmus have been described, the most consistent 
ophthalmic abnormalities are retinal arteriolar at- 
tenuation and mottled pigmentation of the retina 
with prominent loss of perifoveal pigment.‘“’ The 
electroretinogram demonstrates severely reduced 
rod and cone mediated responses. 
The pathologic manifestations of infantile Ref- 
sum’s disease have been documented in only one 
case study by Torvik et al, 14’ who noted micronodu- 
lar liver cirrhosis and hypoplastic but nonatrophic 
adrenal changes. The central nervous system 
showed severe hypoplasia of the cerebellar granu- 
lar layer and reduction of axons and myelin in var- 
ious areas including the optic nerves. Large num- 
bers of perivascular macrophages with bilamellar 
inclusions were present in these areas, but no active 
demyelinative process was seen. There was neuro- 
nal loss in all layers of the retina. 
Shortly after infantile Refsum’s disease was first 
described, further biochemical studies indicated 
that phytanic acid accumulation was not the only 
abnormality. Excessive tissue amounts of very-long- 
chain fatty acids, pipecolic acid, and bile acid inter- 
mediates were discovered,‘6*gs*gg overlapping those 
of the biogenetic peroxisomal disorders, Zellweger 
syndrome and neonatal adrenoleukodystrophy, 
but much less severe. Several investigators have 
now reported a deficiency of peroxisomes in tissues 
from infantile Refsum’s disease patients.6*g”“5*‘5s 
B. PEROXISOMAL DISORDERS RESULTING 
FROM MORE THAN ONE ENZYME DEFICIENCY 
Rhizomelic chondrodysplasia punctata is cur- 
rently the only disorder in this category. There is 
defective plasmalogen synthesis, phytanic acid oxi- 
dation, and abnormal processing of the peroxisom- 
al enzyme thiolase. Unlike the peroxisome biogene- 
sis disorders, peroxisomes are present but may be 
abnormal.5’ 
Due to perturbed synthesis, plasmalogen levels 
are profoundly reduced and are lower than in Zell- 
weger syndrome. 5p,57 Phytanic acid levels are in- 
creased and are comparable to those seen in classi- 
cal Refsum’s disease.5’ However, pipecolic acid, bile 
acid intermediates, and very long chain fatty acid 
levels are normal in rhizomelic chondrodysplasia 
punctata, indicating that some peroxisomal func- 
tions are intact. 
1. Rhizomelic Chondrodysplasia Punctata 
In 1914, Conradi described chondrodysplasia 
punctata as a condition marked by stippling foci of 
calcification in the epiphyses.24 In 1971 Spranger et 
al”’ delineated the rhizomelic form of chondrodys- 
plasia, known as rhizomelic condrodysplasia punc- 
tata, characterized by autosomal recessive inheri- 
tance, shortening of the proximal extremities, 
dermatitis, psychomotor retardation, cataracts, and 
death usually before the end of the first year. Rhizo- 
melic chondrodysplasia punctata was shown to be a 
peroxismal disorder by Heymans et a1.52 They not- 
ed the striking clinical similarities of rhizomelic 
chondrodysplasia punctata to Zellweger syndrome, 
then discovered a deficiency of plasmalogen synthe- 
sis and elevated levels of phytanic acid which are 
indicative of peroxisome dysfunction. 
Rhizomelic chondrodysplasia punctata is to be 
distinguished from Conradi-Hunermann chondro- 
dysplasia, which is an autosomal dominant disease 
with a normal life span and normal intellect. It is 
not a peroxisomal disorder. 
Ocular findings in patients with rhizomelic chon- 
drodysplasia punctata include alternating esotro- 
pia, lateral gaze nystagmus, and wandering eye 
movements. 74 However, cataracts are the most 
prominent and debilitating ophthalmologic mani- 
festation_3*48*74*11g 
A characteristic radiographic manifestation of 
rhizomelic chondrodysplasia punctata is irregular 
calcification (stippling) of the cartilage of the ex- 
tremities.9’37’197 Primary ossification centers may be 
absent in the lower femur, and histologically abnor- 
mal chondrocytes are observed.“’ Clefting of verte- 
bral bodies, cerebral hypoplasia, and reduced neu- 
rons in the cerebrum, cerebellum, medulla, and 
spinal cord have also been reported.74 
Ocular pathologic features consist of bilateral 
anterior capsular cataracts containing acid muco- 
polysaccharides, posterior lenticonus, posterior 
embryotoxon, and hypoplasia of the choroid and 
ciliary body. 74 The cataracts are believed to be histo- 
chemically similar to the usual anterior capsular 
cataract.48*74*“g Hypoplasia of retinal ganglion cells, 
nerve fibers, and optic nerve may also be present.74 
C. PEROXISOME DISORDERS RESULTING 
FROM A DEFICIENCY OF A SINGLE ENZYME 
X-linked adrenoleukodystrophy and primary hy- 
peroxaluria type 1 appear to result from a deficien- 
cy of a single peroxisomal enzyme. Although classi- 
cal Refsum’s disease is also frequently attributed to 
a single peroxisomal enzyme deficiency, definitive 
evidence is lacking. 
The biochemical perturbation observed when the 
peroxisome disorder is caused by a single faulty en- 
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zyme is much more limited than in the peroxisome 
biogenesis disorders. One such example is the very- 
long-chain fatty acid build-up in X-linked adrenoleu- 
kodystrophy because of deficient lignoceroyl-CoA 
synthetase (an acyl-CoA ligase).50~73~‘2g~‘60~162 Primary 
hyperoxaluria type 1 results from a deficiency of 
the peroxisomal enzyme alanine: glyoxylate amino- 
transferase and manifests increased serum levels of 
glyoxalate and oxalate. 26*86 Classical Refsum’s dis- 
ease results from defective phytanic acid oxidation, 
a consequence of deficient phytanic acid alpha-hy- 
droxylase.31f5g However, this reaction has not yet 
been localized to the peroxisome. 
1. X-Linked Adrenoleukodystrophy 
In 1923 Siemerling and Creutzfeldt first recog- 
nized a disorder that manifested adrenal hypofunc- 
tion and cerebral demyelination.1”8 Because the 
children appeared tanned due to adrenal dysfunc- 
tion, and their post-mortem brains and spinal cords 
showed demyelination with gliosis, the authors 
called the condition “bronzed sclerosing encepha- 
lomyelitis.” The condition was later named “adre- 
noleukodystrophy,” and was found to have X- 
linked inheritance.77*85z86 
There are two predominant phenotypes associat- 
ed with X-linked adrenoleukodystrophy: a child- 
hood form, in which visual loss is a prominent fea- 
ture, and an adult form, called adrenomyeloneurop- 
athy, in which color vision deficits have been the 
only reported ophthalmologic disturbance.12’ In 
the childhood form, the first symptoms usually be- 
gin mid-way through the first decade, with emo- 
tional lability and hyperactivity. “Attention deficit 
disorder” is usually diagnosed, but cognitive de- 
cline soon sets in, followed by loss of sight and hear- 
ing, incoordination, and spastic quadriparesis. Ad- 
renal hypofunction is present in nearly all cases, but 
may precede or follow neurologic signs.‘23 Death 
usually supervenes within a decade of onset. 
The visual loss in X-linked adrenoleukodystro- 
phy appears to result from demyelination of any or 
all portions of the visual pathway, from optic nerve 
to visual cortex.‘65*166 A delayed, broad, low ampli- 
tude visual evoked response that becomes extinct 
with time and a normal electroretinogram15’,‘65 are 
consistent with neural visual pathway damage that 
spares the outer retina. 
The central nervous system pathology of X-linked 
adrenoleukodystrophy bears superficial resemblance 
to that seen in Zellweger syndrome and neonatal 
adrenoleukodystrophy, but there are fundamental 
differences.67s123 As in the biogenetic peroxisomal 
disorders, there are macrophages filled with bileaf- 
let inclusions scattered throughout the demyelinat- 
ing regions. But unlike the biogenetic peroxisomal 
disorders, X-linked adrenoleukodystrophy shows 
very severe and focal demyelination, most marked 
in the parietal and occipital lobes. Perivascular lym- 
phocytes are abundant; neurons appear normal. 
There are characteristic striated inclusions in 
Schwann cells, testis, brain, and adrenal cortex 
which represent cholesterol esters of very-long- 
chain fatty acids.62,10',1O2~103~122 
Because these changes are occurring in children 
who are old enough to have myelinated their cere- 
brum, the contrast between normal and abnormal 
areas is striking. It can be imaged with CT and MRI, 
which vividly demonstrate forward progression, 
from occipital to frontal lobes, of areas of low signal 
intensity surrounded by a “torch-like” rim of high 
signal intensity, reflecting breakdown of the blood- 
brain barrier.g” Impressed by the intensity of this 
surrounding inflammatory response, observers have 
wondered if some other disease mechanism besides 
metabolic dysfunction is at work. 
Ocular pathologic studies show loss of the gangli- 
on cell layer151~166 (Fig. 7), and atrophy and gliosis of 
the nerve fiber layer and optic nerve.” Bileaflet- 
bearing macrophages have been found in the optic 
nerve in one case. 23 Unlike the peroxisomal biogen- 
etic disorders, the outer retina remains histological- 
ly normal. 
Although X-linked-adrenoleukodystrophy is the 
most common peroxisomal disorder, it was not un- 
til 1976 that Igarshi et a16* demonstrated that there 
is an accumulation of very-long-chain fatty acids 
present as cholesterol esters in the brain and adre- 
nal tissues from X-linked adrenoleukodystrophy 
patients. The definitive connection came in 1984, 
when Singh et al 130,‘3’ showed that very-long-chain 
fatty acid oxidation is localized to the peroxisome 
and that X-linked adrenoleukodystrophy results 
from its interruption. Since then, the specific bio- 
chemical defect has been identified as a deficiency 
of the peroxisomal enzyme lignoceroyl-CoA synthe- 
tase,50 the first enzyme in the very-long-chain fatty 
acid oxidative pathway, and one that is embedded 
in the peroxisomal membrane. This leads to very- 
long-chain fatty acid accumulation, the only distin- 
guishing biochemical abnormality of X-linked 
adrenoleukodystrophy. The pile-up of very-long- 
chain fatty acids, as dramatic as it is, may not be the 
explanation for neurologic dysfunction, since the 
degree of dysfunction is poorly correlated with the 
levels of very long chain fatty acids.*‘j 
X-linked adrenoleukodystrophy should be sus- 
pected in boys aged under ten years who exhibit 
hyperactive behavior and psychomotor regression 
together with visual loss. Ophthalmologic findings 
include cortical blindness and optic atrophy. The 
diagnosis is made definitively by finding elevated 
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plasma levels of very-long-chain fatty acid. 
The current treatment of childhood X-linked 
adrenoleukodystrophy consists of replacement of 
adrenal steroids and dietary restrictions of fatty 
acid intake. It has been shown that plasma levels of 
very-long-chain fatty acid can be reduced to nor- 
mal levels by special dietary manipulation,629”3 but 
there is no evidence that this will induce improve- 
ment or even stabilization of the disease. Immu- 
nosuppression, used in an attempt to reduce the 
“inflammatory” component of X-linked adrenoleu- 
kodystrophy, has been ineffective.” Aubourg et al4 
have reported reversal of neurologic deficits and 
brain MRI abnormalities in an eight-year-old boy 
treated with bone marrow transplantation. They 
hypothesize that the transplanted marrow cells 
crossed the blood-brain barrier and supplied the 
missing peroxisomal functions. 
2. Primary hyperoxaluria Type 1 
There are two types of genetically determined 
primary hyperoxaluria. Type 1 is an autosomal re- 
cessive disorder which results from a deficiency of 
the peroxisomal enzyme alanine : glyoxylate amino- 
transferase.26*sg Accumulation of glyoxylate and its 
conversion to oxalate result in the deposition of 
oxalate in various tissues, including the eye. Prima- 
ry hyperoxaluria type 1 usually becomes manifest 
during early childhood or adulthood and patients 
present with renal failure or nephrolithiasis.‘33 In- 
fantile onset is correlated with more severe features 
and death due to renal failure. Primary hyperoxal- 
uria type 2 results from a deficiency of D-glycerate 
dehydrogenase and is not a peroxisomal disorder. 
Primary hyperoxaluria type 1 causes in a distinc- 
tive retinal pigmentary disturbance secondary to 
deposition of oxalate. Findings are confined to the 
posterior pole and are bilaterally symmetric. Mild 
cases show small parafoveal subretinal black ring- 
lets with a bright white or yellow center48,“g,‘33 (Fig. 
8). More advanced cases show single large, black, 
well-circumscribed central macular lesions with white 
fibrous material deep to the black area and below 
the sensory retina. These lesions are believed to be 
nonprogressive. Surprisingly, visual acuity tends to 
be unaffected by these lesions.‘33 
The other manifestation of primary hyperoxal- 
uria type 1 is optic disc pallor which may be secon- 
dary to increased intracranial pressure or to retinal 
arteriolar occlusion.“’ Of 24 cases followed at a sin- 
gle institution, three were noted to have optic disc 
pallor. Two of these cases previously had enlarged 
ventricles, papilledema, and increased intracranial 
pressure. ‘33 The third had retinal arteriolar attenu- 
ation believed secondary to oxalate deposition in 
the vessel walls.‘32 Visual acuity was subnormal in all 
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Infantile Refsum’s disease 
Classical Refsum’s disease 
Primary hyperoxaluria type I 
cases. 
The pathologic features of primary hyperoxal- 
uria type 1 consist primarily of renal deposition of 
oxalate which causes nephrolithiasis and nephro- 
calcinosis. Osteodystrophy has been reported and 
may result in pathological fractures with mild trau- 
ma. I3 H Y drocephalus and mental retardation are 
also rarely seen. 13’ 
Ocular pathologic findings in patients with pri- 
mary hyperoxaluria type 1 consist of calcium oxa- 
late crystal deposition in the retinal pigment epithe- 
lium, ciliary body, retina, and ocular muscles.33,42,76, 
‘*‘Jo’ Crystals of oxalate have also been documented 
in the wall of retinal vessels and all vascularized 
ocular tissues, including the conjunctiva, iris, inner 
retinal layers (especially ganglion cell layer), optic 
disc, choroid, and episclera.“j The black pigmented 
lesions of primary hyperoxaluria type 1 are be- 
lieved to represent retinal pigment epithelium hy- 
pertrophy and/or hyperplasia in response to irri- 
tation by oxalate crystal deposition.76 The white 
fibrosis has been postulated to represent subretinal 
neovascularization. Diffuse optic atrophy secondary 
to papilledema may be caused by impeded cerebro- 
spinal fluid drainage due to oxalate crystal deposi- 
tion, in as much as Scowens et al’*’ demonstrated 
elevated calcium oxalate levels in the cerebrospinal 
fluid of a patient with primary hyperoxaluria type 1. 
In the past, patients with primary hyperoxaluria 
type 1 succumbed to renal failure at an early age. 
However, renal transplantation is prolonging sur- 
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viva1 and more patients are living long enough to 
demonstrate ocular lesions. 
prominent. 
3. Classical Refsum’s Disease 
Classical Refsum’s disease, or “heredopathia atac- 
tica polyneuritiformis” was first described in 1945 
by Refsum, who noted night blindness, pigmentary 
retinopathy, hearing loss, peripheral neuropathy 
and ataxia.“‘*‘l’ Other features are an increase in 
the CSF protein level with a normal cell count, car- 
diopathy, skeletal malformations primarily of the 
metatarsals and metacarpals, and skin changes re- 
sembling ichthyosis.4’,‘06.‘O7,lOg~~lI,148 
III. Peroxisomal Disorders and the 
Ophthalmologist 
The peroxisomal disorders must be added to the 
Classical Refsum’s disease may have its onset 
from the first to the third decade, either with night 
blindness, extremity weakness, or ataxia.“’ It runs 
an indolently progressive course with death often 
caused by cardiac arrhythmia. Present in all cases of 
classical Refsum’s disease, the pigmentary retinop- 
athy is granular rather than corpuscular, but other- 
wise quite like typical retinitis pigmentosa in having 
narrowed retinal arterioles, visual fields that show 
ring scotomas and progressive constriction, and 
electroretinography that indicates marked loss of 
rod and cone function.‘06,1’0,148 
The nervous system pathology of classical Ref- 
sum’s disease involves principally the peripheral 
nerves, the spinal cord, and the retina.‘7”8*34’108 The 
rods and cones are almost entirely absent, the outer 
nuclear and outer plexiform layers are completely 
atrophic, the ganglion cells are reduced in number, 
the inner nuclear layer is thinned, and the nerve 
fiber layer is thickened due to gliosis.‘4s Retinal ves- 
sels are narrowed and occluded, their walls swelled 
by lipid material. The pigment epithelium may be 
absent in many areas of the posterior segment. 
Where it is present, it is thickened and loaded with 
lipid. The optic nerves may show demyelination, 
but gliosis has not been reported. The iris sphincter 
and dilator muscles are also infiltrated with lipid. 
list of conditions with inborn errors of metabolism 
that present in infancy or childhood with multior- 
gan dysfunction and retinal abnormalities (Table 
3). The three peroxisomal biogenesis disorders - 
Zellweger syndrome, neonatal adrenoleukodystro- 
phy, and infantile Refsum’s disease - will manifest 
a noncorpuscular pigmentary retinopathy and op- 
tic atrophy. The only peroxisomal disorder caused 
by multiple enzyme abnormalities - rhizomelic 
chondrodysplasia punctata - will present ophthal- 
mologically with cataract. Of the three disorders 
attributable to a single enzyme defect, X-linked 
adrenoleukodystrophy will usually manifest optic 
atrophy but the retina will appear normal; primary 
hyperoxaluria type 1 has distinctive posterior pole 
retinal findings of black parafoveal ringlets sur- 
rounding yellow-white patches; classical Refsum’s 
disease manifests a pigmentary retinopathy similar 
to that of Zellweger syndrome and neonatal adren- 
oleukodystrophy. The ophthalmologist should be 
aware of the genetic implications of these disorders, 
that biochemical tests now exist for rapid, even pre- 
natal, diagnosis, 19.46,72.82,64,114,116,117, 125,157,161 and that 
in two disorders (classical Refsum’s disease, X-linked 






Whether classical Refsum’s disease is truly a per- 
oxisomal disorder is still unsettled. An elevation of 
phytanic acid and reduced phytanic acid oxidation 
are the only biochemical markers of this dis- 
ease.31,5’*‘11 Although similar disturbances are 
found in the peroxisomal biogenesis disorders, and 
administration of a phytanic acid precursor leads to 
peroxisomal proliferation, there is yet no proof that 






Classical Refsum’s disease appears to be a rare 
disease outside northern Europe, but its diagnosis 
is important because a diet free of phytol arrests 
and may reverse its course.2g,65*‘40*141 The ophthal- 
mologist may have the first opportunity to make the 
diagnosis, since the ocular signs are often the most 
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